Tripep AB (publ.)—Interim Report—January - March 2007 Corporate identity number: 556705-1965

Tripep AB (publ.)—Interim Report—January - March 2007 Corporate identity number:
556705-1965

• Research and development costs amounted to SEK 3.4 million. 
• The loss after tax was SEK -6.5 million. 
• Earnings per share were SEK -0.13. 
• The company had no net sales in the period.
• Thomas Lynch was elected Chairman at the Extraordinary General Meeting (EGM)
on 25 January.
• Agreement with Kringle Pharma of Japan on the joint development of Tripep's
ChronSeal project.

(there is no comparative data because the company was incorporated in June 2006)



For more information, please contact:

Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63
E-mail: jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se


Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The share is quoted on First North. For more information, please refer
to the company's Website: www.tripep.se